{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:22:46Z","timestamp":1773328966854,"version":"3.50.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11239-019-01849-2","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T08:03:47Z","timestamp":1555661027000},"page":"14-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians"],"prefix":"10.1007","volume":"48","author":[{"given":"Radha","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Athar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atif","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-7707","authenticated-orcid":false,"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"issue":"5","key":"1849_CR1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/hae.12243","volume":"19","author":"R Lassila","year":"2013","unstructured":"Lassila R, Lindberg O (2013) Erik von Willebrand. Haemophilia 19(5):643\u2013647","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"1849_CR2","first-page":"2","volume":"32","author":"ZM Ruggeri","year":"2000","unstructured":"Ruggeri ZM (2000) Role of von Willebrand factor in platelet thrombus formation. Ann Med 32(Suppl 1):2\u20139","journal-title":"Ann Med"},{"key":"1849_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.medengphy.2017.06.044","volume":"48","author":"B Huisman","year":"2017","unstructured":"Huisman B et al (2017) Modeling the cleavage of von Willebrand factor by ADAMTS13 protease in shear flow. Med Eng Phys 48:14\u201322","journal-title":"Med Eng Phys"},{"key":"1849_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","volume":"67","author":"JE Sadler","year":"1998","unstructured":"Sadler JE (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67:395\u2013424","journal-title":"Annu Rev Biochem"},{"issue":"19","key":"1849_CR5","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1182\/blood-2010-09-267492","volume":"117","author":"KM Valentijn","year":"2011","unstructured":"Valentijn KM et al (2011) Functional architecture of Weibel\u2013Palade bodies. Blood 117(19):5033\u20135043","journal-title":"Blood"},{"issue":"5","key":"1849_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1055\/s-0036-1579641","volume":"42","author":"EJ Favaloro","year":"2016","unstructured":"Favaloro EJ, Pasalic L, Curnow J (2016) Type 2 M and Type 2A von Willebrand disease: similar but Different. Semin Thromb Hemost 42(5):483\u2013497","journal-title":"Semin Thromb Hemost"},{"issue":"30","key":"1849_CR7","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.1074\/jbc.M117.788992","volume":"292","author":"ER Xu","year":"2017","unstructured":"Xu ER, Blythe EE (2017) Structural analyses of von Willebrand factor C domains of collagen 2A and CCN3 reveal an alternative mode of binding to bone morphogenetic protein-2. J Biol Chem 292(30):12516\u201312527","journal-title":"J Biol Chem"},{"key":"1849_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-bioeng-071516-044539","volume":"19","author":"LDC Casa","year":"2017","unstructured":"Casa LDC, Ku DN (2017) Thrombus formation at high shear rates. Annu Rev Biomed Eng 19:415\u2013433","journal-title":"Annu Rev Biomed Eng"},{"issue":"16","key":"1849_CR9","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2013-11-538173","volume":"123","author":"CJ Lynch","year":"2014","unstructured":"Lynch CJ, Lane DA, Luken BM (2014) Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF. Blood 123(16):2585\u20132592","journal-title":"Blood"},{"issue":"5932","key":"1849_CR10","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1126\/science.1170905","volume":"324","author":"X Zhang","year":"2009","unstructured":"Zhang X et al (2009) Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 324(5932):1330\u20131334","journal-title":"Science"},{"issue":"1","key":"1849_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0250-474X.89751","volume":"73","author":"KP Bharati","year":"2011","unstructured":"Bharati KP, Prashanth UR (2011) Von Willebrand disease: an overview. Indian J Pharm Sci 73(1):7\u201316","journal-title":"Indian J Pharm Sci"},{"issue":"19","key":"1849_CR12","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1182\/blood-2010-02-269266","volume":"116","author":"KM Dayananda","year":"2010","unstructured":"Dayananda KM et al (2010) von Willebrand factor self-association on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood 116(19):3990\u20133998","journal-title":"Blood"},{"issue":"1","key":"1849_CR13","first-page":"14278","volume":"7","author":"K Rack","year":"2017","unstructured":"Rack K, Huck V (2017) Margination and stretching of von Willebrand factor in the blood stream enable adhesion. 7(1):14278","journal-title":"Margination and stretching of von Willebrand factor in the blood stream enable adhesion."},{"issue":"26","key":"1849_CR14","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1182\/blood-2017-04-780825","volume":"130","author":"DM Coenen","year":"2017","unstructured":"Coenen DM, Mastenbroek TG (2017) Cosemans, J, Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 130(26):2819\u20132828","journal-title":"Blood."},{"issue":"2","key":"1849_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/beha.2001.0137","volume":"14","author":"D Meyer","year":"2001","unstructured":"Meyer D et al (2001) Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best Pract Res Clin Haematol 14(2):349\u2013364","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"1849_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00894-004-0194-9","volume":"10","author":"JJ Sutherland","year":"2004","unstructured":"Sutherland JJ et al (2004) Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model 10(4):259\u2013270","journal-title":"J Mol Model"},{"issue":"32","key":"1849_CR17","doi-asserted-by":"publisher","first-page":"29633","DOI":"10.1074\/jbc.M301385200","volume":"278","author":"JF Dong","year":"2003","unstructured":"Dong JF et al (2003) ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 278(32):29633\u201329639","journal-title":"J Biol Chem"},{"issue":"8","key":"1849_CR18","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1046\/j.1538-7836.2003.00359.x","volume":"1","author":"SA Brown","year":"2003","unstructured":"Brown SA et al (2003) Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 1(8):1714\u20131717","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1849_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1365-2141.2008.07311.x","volume":"143","author":"M Sztukowska","year":"2008","unstructured":"Sztukowska M et al (2008) Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 143(1):107\u2013114","journal-title":"Br J Haematol"},{"issue":"7","key":"1849_CR20","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","volume":"111","author":"L Gallinaro","year":"2008","unstructured":"Gallinaro L et al (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111(7):3540\u20133545","journal-title":"Blood"},{"issue":"6","key":"1849_CR21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","volume":"69","author":"JC Gill","year":"1987","unstructured":"Gill JC et al (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69(6):1691\u20131695","journal-title":"Blood"},{"issue":"5","key":"1849_CR22","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1182\/blood-2008-01-133181","volume":"112","author":"CJ Schooten van","year":"2008","unstructured":"van Schooten CJ et al (2008) Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 112(5):1704\u20131712","journal-title":"Blood"},{"issue":"16","key":"1849_CR23","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1182\/blood-2013-03-493312","volume":"122","author":"C Casari","year":"2013","unstructured":"Casari C et al (2013) Accelerated uptake of VWF\/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood 122(16):2893\u20132902","journal-title":"Blood"},{"issue":"6","key":"1849_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nm1760","volume":"14","author":"PK Grewal","year":"2008","unstructured":"Grewal PK et al (2008) The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 14(6):648\u2013655","journal-title":"Nat Med"},{"issue":"12","key":"1849_CR25","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3324\/haematol.2012.063297","volume":"97","author":"JN Pegon","year":"2012","unstructured":"Pegon JN et al (2012) Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica 97(12):1855\u20131863","journal-title":"Haematologica"},{"issue":"2","key":"1849_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0049-3848(01)00243-2","volume":"102","author":"N Christodoulides","year":"2001","unstructured":"Christodoulides N et al (2001) Glycoprotein Ib\/IX\/V binding to the membrane skeleton maintains shear-induced platelet aggregation. Thromb Res 102(2):133\u2013142","journal-title":"Thromb Res"},{"issue":"6","key":"1849_CR27","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/j.1538-7836.2005.01384.x","volume":"3","author":"W Jy","year":"2005","unstructured":"Jy W et al (2005) Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor\/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 3(6):1301\u20131308","journal-title":"J Thromb Haemost"},{"key":"1849_CR28","doi-asserted-by":"crossref","unstructured":"Yuan, Y., et al., Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alphaIIbbeta3) in von Willebrand factor-induced signal transduction. J Biol Chem, 1997. 272(35): p. 21847-54","DOI":"10.1074\/jbc.272.35.21847"},{"issue":"2","key":"1849_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/blood-2018-01-769018","volume":"132","author":"AM Randi","year":"2018","unstructured":"Randi AM, Smith KE, Castaman G (2018) von Willebrand factor regulation of blood vessel formation. Blood 132(2):132\u2013140","journal-title":"Blood"},{"issue":"1","key":"1849_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1172\/JCI106480","volume":"50","author":"TS Zimmerman","year":"1971","unstructured":"Zimmerman TS, Ratnoff OD, Powell AE (1971) Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand\u2019s dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 50(1):244\u2013254","journal-title":"J Clin Invest"},{"key":"1849_CR31","doi-asserted-by":"crossref","unstructured":"Boender, J., et al., Clinically relevant differences between assays for von Willebrand factor activity. J Thromb Haemost, 2018","DOI":"10.1111\/jth.14319"},{"issue":"1","key":"1849_CR32","first-page":"75","volume":"43","author":"S Just","year":"2017","unstructured":"Just S (2017) Laboratory Testing for von Willebrand Disease: the Past, Present, and Future State of Play for von Willebrand Factor Assays that Measure Platelet Binding Activity, with or without Ristocetin. Semin Thromb Hemost 43(1):75\u201391","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"1849_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","volume":"14","author":"WL Nichols","year":"2008","unstructured":"Nichols WL et al (2008) von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 14(2):171\u2013232","journal-title":"Haemophilia"},{"key":"1849_CR34","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2147\/CIA.S136931","volume":"13","author":"J Chapin","year":"2018","unstructured":"Chapin J (2018) Von Willebrand disease in the elderly: clinical perspectives. Clin Interv Aging 13:1531\u20131541","journal-title":"Clin Interv Aging"},{"key":"1849_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.thromres.2018.04.015","volume":"166","author":"EJ Favaloro","year":"2018","unstructured":"Favaloro EJ et al (2018) Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: a large international cross-laboratory study. Thromb Res 166:96\u2013105","journal-title":"Thromb Res"},{"issue":"25","key":"1849_CR36","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","volume":"117","author":"A Tiede","year":"2011","unstructured":"Tiede A et al (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777\u20136785","journal-title":"Blood"},{"issue":"4","key":"1849_CR37","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/rth2.12150","volume":"2","author":"S Deconinck","year":"2018","unstructured":"Deconinck S et al (2018) Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome. Res Pract Thromb Haemost 2(4):762\u2013766","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"1849_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ijcard.2014.07.104","volume":"176","author":"HC Waldow","year":"2014","unstructured":"Waldow HC et al (2014) Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol 176(3):739\u2013745","journal-title":"Int J Cardiol"},{"issue":"4","key":"1849_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5830\/CVJA-2015-093","volume":"27","author":"FK Binnetoglu","year":"2016","unstructured":"Binnetoglu FK et al (2016) Acquired von Willebrand syndrome in children with aortic and pulmonary stenosis. Cardiovasc J Afr 27(4):222\u2013227","journal-title":"Cardiovasc J Afr"},{"key":"1849_CR40","doi-asserted-by":"crossref","unstructured":"Massyn, M.W. and S.A. Khan, Heyde syndrome: a common diagnosis in older patients with severe aortic stenosis. Age Ageing, 2009. 38(3): p. 267-70; discussion 251","DOI":"10.1093\/ageing\/afp019"},{"issue":"2","key":"1849_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1160\/TH09-11-0779","volume":"103","author":"TE Warkentin","year":"2010","unstructured":"Warkentin TE, Moore JC (2010) Heyde\u2019s syndrome: from controversy to mainstream. Thromb Haemost 103(2):251\u2013253","journal-title":"Thromb Haemost"},{"issue":"4","key":"1849_CR42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMoa022831","volume":"349","author":"A Vincentelli","year":"2003","unstructured":"Vincentelli A et al (2003) Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349(4):343\u2013349","journal-title":"N Engl J Med"},{"key":"1849_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.thromres.2018.07.028","volume":"170","author":"H Ibrahim","year":"2018","unstructured":"Ibrahim H, Rondina MT, Kleiman NS (2018) Von Willebrand factor and the aortic valve: concepts that are important in the transcatheter aortic valve replacement era. Thromb Res 170:20\u201327","journal-title":"Thromb Res"},{"issue":"4","key":"1849_CR44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1505643","volume":"375","author":"E Belle Van","year":"2016","unstructured":"Van Belle E et al (2016) Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. N Engl J Med 375(4):335\u2013344","journal-title":"N Engl J Med"},{"issue":"2","key":"1849_CR45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1055\/s-0038-1647035","volume":"60","author":"P Froom","year":"1988","unstructured":"Froom P et al (1988) Von Willebrand factor and mitral valve prolapse. Thromb Haemost 60(2):230\u2013231","journal-title":"Thromb Haemost"},{"issue":"3","key":"1849_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4065\/mcp.2010.0309","volume":"86","author":"JL Blackshear","year":"2011","unstructured":"Blackshear JL et al (2011) Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy. Mayo Clin Proc 86(3):219\u2013224","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"1849_CR47","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2141.2011.08732.x","volume":"155","author":"G Onimoe","year":"2011","unstructured":"Onimoe G et al (2011) Acquired von Willebrand Syndrome in congenital heart disease: does it promote an increased bleeding risk? Br J Haematol 155(5):622\u2013624","journal-title":"Br J Haematol"},{"issue":"2","key":"1849_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0033-1334867","volume":"39","author":"AB Federici","year":"2013","unstructured":"Federici AB et al (2013) Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 39(2):191\u2013201","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"1849_CR49","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/01.STR.0000244767.39962.f7","volume":"37","author":"TN Bongers","year":"2006","unstructured":"Bongers TN et al (2006) High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37(11):2672\u20132677","journal-title":"Stroke"},{"issue":"23","key":"1849_CR50","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1182\/blood-2015-12-688010","volume":"127","author":"G Pedrazzini","year":"2016","unstructured":"Pedrazzini G et al (2016) Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI. Blood 127(23):2934\u20132936","journal-title":"Blood"},{"issue":"20","key":"1849_CR51","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1182\/blood-2015-09-667642","volume":"126","author":"M Jacquemin","year":"2015","unstructured":"Jacquemin M, Peerlinck K (2015) Free hemoglobin: a boost to platelet thrombi. Blood 126(20):2262\u20132263","journal-title":"Blood"},{"issue":"3","key":"1849_CR52","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/jth.13933","volume":"16","author":"R Muslem","year":"2018","unstructured":"Muslem R, Caliskan K, Leebeek FWG (2018) Acquired coagulopathy in patients with left ventricular assist devices. J Thromb Haemost 16(3):429\u2013440","journal-title":"J Thromb Haemost"},{"issue":"17","key":"1849_CR53","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood-2013-10-530428","volume":"123","author":"Q Da","year":"2014","unstructured":"Da Q et al (2014) Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. Blood 123(17):2715\u20132721","journal-title":"Blood"},{"issue":"7","key":"1849_CR54","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/MBC.0000000000000635","volume":"28","author":"SN Selvam","year":"2017","unstructured":"Selvam SN et al (2017) Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients. Blood Coagul Fibrinolysis 28(7):521\u2013533","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"1849_CR55","doi-asserted-by":"publisher","first-page":"e004638","DOI":"10.1161\/CIRCHEARTFAILURE.117.004638","volume":"11","author":"CR Bartoli","year":"2018","unstructured":"Bartoli CR et al (2018) Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis. Circ Heart Fail 11(9):e004638","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1849_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1313385","volume":"370","author":"RC Starling","year":"2014","unstructured":"Starling RC et al (2014) Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370(1):33\u201340","journal-title":"N Engl J Med"},{"issue":"6","key":"1849_CR57","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1160\/TH08-10-0677","volume":"101","author":"Z Zhou","year":"2009","unstructured":"Zhou Z et al (2009) Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 101(6):1070\u20131077","journal-title":"Thromb Haemost"},{"issue":"8","key":"1849_CR58","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/MBC.0b013e32834c73f9","volume":"22","author":"MR Arkebauer","year":"2011","unstructured":"Arkebauer MR et al (2011) Carbon monoxide and nitric oxide modulate alpha(2)-antiplasmin and plasmin activity: role of heme. Blood Coagul Fibrinolysis 22(8):712\u2013719","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"1849_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jchf.2013.10.008","volume":"2","author":"AL Meyer","year":"2014","unstructured":"Meyer AL et al (2014) Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2(2):141\u2013145","journal-title":"JACC Heart Fail"},{"issue":"1 Pt 1","key":"1849_CR60","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0006-3495(04)74136-3","volume":"86","author":"H Shankaran","year":"2004","unstructured":"Shankaran H, Neelamegham S (2004) Hydrodynamic forces applied on intercellular bonds, soluble molecules, and cell-surface receptors. Biophys J 86(1 Pt 1):576\u2013588","journal-title":"Biophys J"},{"issue":"2","key":"1849_CR61","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2007-05-093021","volume":"111","author":"K Shim","year":"2008","unstructured":"Shim K et al (2008) Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 111(2):651\u2013657","journal-title":"Blood"},{"issue":"1","key":"1849_CR62","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.healun.2003.10.018","volume":"24","author":"GV Letsou","year":"2005","unstructured":"Letsou GV et al (2005) Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 24(1):105\u2013109","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"1849_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.healun.2013.10.005","volume":"33","author":"N Uriel","year":"2014","unstructured":"Uriel N et al (2014) Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant 33(1):51\u201359","journal-title":"J Heart Lung Transplant"},{"issue":"19","key":"1849_CR64","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.jacc.2018.02.075","volume":"71","author":"F Vincent","year":"2018","unstructured":"Vincent F et al (2018) Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support. J Am Coll Cardiol 71(19):2106\u20132118","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1849_CR65","first-page":"96","volume":"112","author":"MA Brehm","year":"2014","unstructured":"Brehm MA et al (2014) von Willebrand disease type 2A phenotypes IIC, IID and IIE: a day in the life of shear-stressed mutant von Willebrand factor. Thromb Haemost 112(1):96\u2013108","journal-title":"Thromb Haemost"},{"issue":"1","key":"1849_CR66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/rth2.12064","volume":"2","author":"DA Keesler","year":"2018","unstructured":"Keesler DA, Flood VH (2018) Current issues in diagnosis and treatment of von Willebrand disease. Research and Practice in Thrombosis and Haemostasis 2(1):34\u201341","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"1","key":"1849_CR67","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.healun.2014.09.013","volume":"34","author":"K Draper","year":"2015","unstructured":"Draper K et al (2015) Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 34(1):132\u2013134","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"1849_CR68","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","volume":"5","author":"A Borel-Derlon","year":"2007","unstructured":"Borel-Derlon A et al (2007) Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 5(6):1115\u20131124","journal-title":"J Thromb Haemost"},{"issue":"6","key":"1849_CR69","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/CRD.0000000000000202","volume":"26","author":"L Grosman-Rimon","year":"2018","unstructured":"Grosman-Rimon L et al (2018) The Physiological Rationale for Incorporating Pulsatility in Continuous-Flow Left Ventricular Assist Devices. Cardiol Rev 26(6):294\u2013301","journal-title":"Cardiol Rev"},{"issue":"4","key":"1849_CR70","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/MAT.0000000000000766","volume":"64","author":"AL Edwards","year":"2018","unstructured":"Edwards AL et al (2018) Association of Pulsatility with Gastrointestinal Bleeding in a Cohort of HeartMate II Recipients. ASAIO J 64(4):472\u2013479","journal-title":"ASAIO J"},{"issue":"1","key":"1849_CR71","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/MAT.0000000000000449","volume":"63","author":"LC Halder","year":"2017","unstructured":"Halder LC et al (2017) Time in Therapeutic Range for Left Ventricular Assist Device Patients Anticoagulated With Warfarin: a Correlation to Clinical Outcomes. ASAIO J 63(1):37\u201340","journal-title":"ASAIO J"},{"issue":"4","key":"1849_CR72","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/MAT.0000000000000758","volume":"64","author":"TL Molina","year":"2018","unstructured":"Molina TL et al (2018) Gastrointestinal Bleeding in Left Ventricular Assist Device: octreotide and Other Treatment Modalities. ASAIO J 64(4):433\u2013439","journal-title":"ASAIO J"},{"issue":"4","key":"1849_CR73","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/MAT.0000000000000433","volume":"63","author":"IB Hollis","year":"2017","unstructured":"Hollis IB et al (2017) Inhaled Desmopressin for Refractory Gastrointestinal Bleeding in a Patient With a HeartMate II Left Ventricular Assist Device. ASAIO J 63(4):e47\u2013e49","journal-title":"ASAIO J"},{"issue":"10","key":"1849_CR74","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/j.1538-7836.2005.01435.x","volume":"3","author":"J Goudemand","year":"2005","unstructured":"Goudemand J et al (2005) Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation\/removal methods. J Thromb Haemost 3(10):2219\u20132227","journal-title":"J Thromb Haemost"},{"issue":"6","key":"1849_CR75","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.V89.6.1954","volume":"89","author":"HM Tsai","year":"1997","unstructured":"Tsai HM et al (1997) Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834\u00a0W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 89(6):1954\u20131962","journal-title":"Blood"},{"issue":"5","key":"1849_CR76","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1160\/th14-02-0148","volume":"112","author":"A Rauch","year":"2014","unstructured":"Rauch A et al (2014) Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. Thromb Haemost 112(5):1014\u20131023","journal-title":"Thromb Haemost"},{"issue":"13","key":"1849_CR77","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","volume":"25","author":"PJ Lenting","year":"2015","unstructured":"Lenting PJ, Christophe OD, Denis CV (2015) von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 25(13):2019\u20132028","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-019-01849-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T23:06:13Z","timestamp":1587164773000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-019-01849-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1849"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-01849-2","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,19]]},"assertion":[{"value":"19 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}